Looking back, what a journey! We remember well when we first started working with Thomas Baumert in late 2017. Built on many years of transformational…
Overall, investment in Swiss biotech companies almost tripled on the previous year’s figure. It amounted to 3.44 billion Swiss francs. Investment in research and development…
Synendos is developing first-in-class inhibitors. These inhibitors modulate a newly identified drug target in the body’s endocannabinoid system which is a key neuromodulator system in…
The term "bifunctional molecules" covers a collection of related modalities with different but similar strategies. They are opening up once-inaccessible targets and enabling the development…
Under the current tax framework, the non-uniform cantonal tax practices on the capital gains treatment and valuation of employee shares lead to different tax consequences…
Nowadays, biotech headlines usually talk about hundred million series A financings, oversubscribed IPOs, or multi-billion exits. But success is not guaranteed at all, even when…
In this paper, "Driving value from genomics in life sciences: rising to the data challenge", KPMG explores the cornerstone for genomic data leadership: a robust…
“We are very excited to announce this partnership with Walder Wyss. They have advised several of our companies during their financing rounds and we have…